Safety and efficacy of first-generation and second-generation drug-eluting stents in the setting of acute coronary syndromes

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Cardiovascular Medicine

• Publication date

  2014-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2459/JCM.0b013e328365c0fcPMID 24922044
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes.

  2015cited by this paper
• Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY).

  2013cited by this paper
• Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation.

  2013cited by this paper
• Realigning Venus and Mars: The sexual equality of STEMI patients

  2013cited by this paper
• Clinical outcomes in real‐world patients with acute myocardial infarction receiving XIENCE V® everolimus‐eluting stents

  2013cited by this paper
• Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.

  2013cited by this paper
• Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials

  2012cited by this paper
• Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.

  2012cited by this paper
• Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents in ST elevation myocardial infarction: findings from the Guthrie Health Off-label Stent (GHOST) Registry.

  2012cited by this paper
• Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial.

  2012cited by this paper
• Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.

  2012cited by this paper
• Outcomes of management of acute coronary syndrome in patients with congenital bleeding disorders: a single center experience and review of the literature.

  2012cited by this paper
• Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis

  2012cited by this paper
• Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.

  2012cited by this paper
• Long-term comparison of everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes.

  2012cited by this paper
• Zotarolimus‐eluting vs. sirolimus‐eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy

  2012cited by this paper
• Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis.

  2012cited by this paper
• Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents following successful PCI in non-ST-elevation myocardial infarction: findings from the Guthrie Health Off-Label StenT (GHOST) Registry.

  2012cited by this paper
• Four‐year clinical follow‐up of the XIENCE V everolimus‐eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial

  2011cited by this paper
• Long-term safety and efficacy of sirolimus- vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial.

  2011cited by this paper
• Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).

  2011cited by this paper
• Three-year clinical outcome with the Endeavor™ zotarolimus-eluting stent in primary percutaneous coronary intervention for ST elevation myocardial infarction: the Endeavor™ primary PCI study (E-PPCI).

  2011cited by this paper
• Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.

  2011cited by this paper
• Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

  2011cited by this paper
• Long-term clinical outcome in STEMI patients treated with primary PCI and drug-eluting or bare-metal stents: insights from a high-volume single-center registry.

  2011cited by this paper
• Comparison of outcomes for patients receiving drug-eluting versus bare metal stents for non-ST-segment elevation myocardial infarction.

  2011cited by this paper
• 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Ele

  2011cited by this paper
• Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings

  2011cited by this paper
• Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

  2010cited by this paper
• Comparison of outcomes between Zotarolimus- and sirolimus-eluting stents in patients with ST-segment elevation acute myocardial infarction.

  2010cited by this paper
• Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial.

  2010cited by this paper
• A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.

  2010cited by this paper
• Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.

  2010cited by this paper
• Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.

  2010cited by this paper
• Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study).

  2010cited by this paper
• Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.

  2010cited by this paper
• Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial.

  2010cited by this paper
• Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial.

  2010cited by this paper
• The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.

  2009cited by this paper
• The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.

  2009cited by this paper
• Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.

  2009cited by this paper
• Effect of drug-eluting stents on frequency of repeat revascularization in patients with unstable angina pectoris or non-ST-elevation myocardial infarction.

  2009cited by this paper
• Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial.

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events.

  2008cited by this paper
• Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.

  2008cited by this paper
• CORONARY ARTERY DISEASE Original Studies Outcomes With Drug-Eluting Stents Versus Bare Metal Stents in Acute ST-Elevation Myocardial Infarction: Results From the Strategic Transcatheter Evaluation of New Therapies (STENT) Group

  2008cited by this paper
• Drug-eluting or bare-metal stents for acute myocardial infarction.

  2008cited by this paper
• Endothelial cell recovery between comparator polymer-based drug-eluting stents.

  2008cited by this paper
• Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.

  2007cited by this paper
• Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI).

  2007cited by this paper
• Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).

  2007cited by this paper
• Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial.

  2007cited by this paper
• Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION).

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.

  2007cited by this paper
• Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

  2006cited by this paper
• Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention.

  2006cited by this paper
• Sirolimus-eluting versus uncoated stents in acute myocardial infarction.

  2006cited by this paper
• Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.

  2005cited by this paper
• Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial.

  2005cited by this paper
• Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction.

  2004cited by this paper
• Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious?

  2004cited by this paper
• Usefulness of a cobalt chromium coronary stent alloy.

  2003cited by this paper
• TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions

  2003cited by this paper
• Bench to bedside: the development of rapamycin and its application to stent restenosis.

  2001cited by this paper
• Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty.

  1987cited by this paper
• Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty.

  1979cited by this paper

• Role of Second-Generation Drug-Eluting Stents and Bypass Grafting in Coronary Artery Disease: A Systematic Review and Meta-analysis

  2017cites this paper
• Oxidative stress induces early-onset apoptosis of vascular smooth muscle cells and neointima formation in response to injury

  2015cites this paper